Global Biosimilar Market Projected to Reach USD 282.3 Billion by 2035

The global biosimilar market was valued at approximately USD 36.79 billion in 2024 and is projected to grow significantly by 2035, supported by patent expirations of major biologics, increasing healthcare expenditure, and supportive regulatory frameworks that encourage biosimilar development and uptake. Biosimilars are biologic products that are highly similar to already approved reference biologics, offering comparable safety and efficacy while reducing treatment costs.

The biosimilar market is experiencing strong global growth due to increasing patent expirations of blockbuster biologics. Rising healthcare cost pressures are accelerating the adoption of cost-effective biosimilar alternatives. Regulatory agencies such as the U.S. FDA and EMA are streamlining approval pathways, supporting faster market entry.

A significant number of high-revenue biologics are losing patent protection, creating opportunities for biosimilar manufacturers to enter the market. Healthcare systems worldwide are under pressure to reduce expenditures, and biosimilars offer significant cost savings compared to originator biologics. Increasing cases of cancer, diabetes, rheumatoid arthritis, and other chronic conditions are driving demand for affordable biologic treatments.

Infliximab leads the market in 2024 as a monoclonal antibody used specifically in autoimmune diseases such as rheumatoid arthritis and Crohn's disease, offering cost-efficient biological treatments following the patent expiration of Remicade. Other key molecules include insulin glargine for diabetes management, epoetin alfa for treating anemia associated with chronic kidney disease and chemotherapy, etanercept for autoimmune diseases including rheumatoid arthritis and psoriasis, and filgrastim which stimulates white blood cell production in cancer patients undergoing chemotherapy.

Autoimmune diseases lead the market in 2024, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where biosimilars provide affordable treatment for chronic conditions. Oncology represents a growing segment with biosimilars addressing various cancer types, reducing treatment costs significantly. Cancer treatments represent one of the largest revenue segments, with multiple biosimilars entering this high-demand therapeutic area.

Europe leads in biosimilar adoption, while North America and Asia-Pacific are witnessing rapid expansion. Countries in Asia-Pacific and Latin America are strengthening domestic biosimilar production capabilities to reduce dependency on expensive biologics. Increasing strategic partnerships, mergers, and co-development agreements are reshaping the competitive landscape.

India's biosimilar market was valued at USD 1,016.72 million in 2025 and is projected to reach USD 4,022.58 million by 2034, growing at a compound annual growth rate of 16.51% during the forecast period from 2026-2034. The market expansion is driven by rising demand for affordable biologic therapies, increased chronic and autoimmune disease prevalence, and strengthening domestic manufacturing capabilities.

The Indian Government and regulatory authorities are encouraging the development of biosimilars by simplifying the approval process, and pharmaceutical companies are investing in research, clinical trials and commercializing biosimilars in India. With large scale pharmaceutical manufacturing, India has moved toward accelerated biosimilar production, as large domestic Indian corporations grow investments in biotechnology plants and research centers, and take up partnerships to build biosimilar portfolios, globally.

Indian pharmaceutical companies are gaining entry into global biosimilars markets through partnerships, licensing, and export, making India a key supplier of inexpensive biosimilars globally. In order to penetrate regulated foreign markets, Indian biosimilar manufacturers have been forming partnerships and getting regulatory approval.

Advances in cell line development, analytical characterization, and manufacturing technologies are improving efficiency and reducing production costs. High-resolution analysis supports demonstration of biosimilarity with reference products. Optimized facility design and process efficiency reduce production costs and improve affordability.

Improved clinical data and regulatory confidence are increasing physician and patient acceptance of biosimilars as safe and effective alternatives. Healthcare practitioners and patients are becoming more familiar with and accepting of the safety and reliability of biosimilars. Education and clinical data ensure that the use of biosimilars is widely accepted throughout healthcare environments.

Clear regulatory guidelines and abbreviated approval pathways in major markets are facilitating product launches. Alignment of global regulatory expectations accelerates product approvals and market entry. Supportive pricing frameworks and reimbursement incentives are promoting biosimilar uptake in public healthcare systems.